Non-occlusive, transdermal or transmucosal pharmaceutical formulation comprising: testosterone as active ingredient； and a solvent system present in an amount sufficient to solubilize the active ingredient and characterized in that it includes: (i) a pharmaceutically acceptable diethylene glycol monoalkyl ether present in an amount between about 1% and 30% by weight of the solvent system ； (ii) a pharmaceutically acceptable glycol present in an amount of between about 1% and 30% by weight of the solvent system, with the diethylene glycol monoalkyl ether and glycol being present in a weight ratio of 1: 4 to 1: 10； (iii) a mixture of a C2 to C4 alcohol and water, the mixture being present in an amount between about 40% and 98% of the solvent system, in which the C2 to C4 alcohol is present in an amount of about 5% to 80% of the mixture, and water is present in an amount of about 20% to 95% of the mixture； and (iv) in which the diethylene glycol monoalkyl ether and the glycol in combination are present in an amount of at least 15% and not more than 60% of the formulation, so that, compared to formulations containing the same components but in different amounts and reasons, the present solvent system (a) inhibits the crystallization of the at least one active ingredient on a mucosal surface or the skin of a mammal, (b) reduces or prevents the transfer of the formulation to garments of clothing or another being, (c) modulates the biodistribution of at least one active ingredient within different layers of the skin, (d) facilitates the absorption of at least one active ingredient by a mucous surface or the skin of a mammal or (e) provides a combination of one or more of (a) to (d).Formulación farmacéutica no oclusiva, transdérmica o transmucosa que comprende: testosterona como principio activo； y un sistema de disolventes presente en una cantidad suficiente para solubilizar el principio activo y caracterizado porque incluye: (i) un monoalquil éter de dietilenglicol farmac
